Related Experiment Videos
Short term prophylaxis against heterotopic bone after cementless hip replacement
C Wurnig1, V Auersperg, N Boehler
1Department of Orthopaedics, University of Vienna, Wahringer Gurtel, Austria.
Clinical Orthopaedics and Related Research
|January 1, 1997
Summary
Seven days of indomethacin effectively prevents severe heterotopic ossification after hip replacement, matching 14-day regimens. This offers a shorter, comparable treatment for preventing bone growth after cementless total hip arthroplasty.
Area of Science:
- Orthopedic Surgery
- Pharmacology
Background:
- Heterotopic ossification (HO) is a common complication after cementless total hip arthroplasty.
- Nonsteroidal anti-inflammatory drugs, such as indomethacin, are frequently used to prevent HO.
Purpose of the Study:
- To determine if a 7-day indomethacin regimen is as effective as a 14-day regimen in preventing HO after cementless total hip arthroplasty.
Main Methods:
- A randomized controlled trial comparing 7-day and 14-day indomethacin treatment post-surgery.
- Patients (n=201) received either 100 mg of indomethacin daily for 7 or 14 days.
- HO incidence and severity were assessed at 1-year follow-up using Brooker classification.
Main Results:
- No significant difference in HO incidence or severity between the 7-day and 14-day indomethacin groups.
- Average Harris Hip Scores were comparable (91 vs. 89).
- Adverse events (headache, dizziness, gastritis) were similar and mild in both groups.
Conclusions:
- A 7-day indomethacin treatment is sufficient for preventing severe heterotopic ossification after cementless total hip arthroplasty.
- Shorter indomethacin duration offers comparable efficacy with potentially reduced side effects.